GPV02

GPV02 is a glycoengineered protein subunit vaccine currently in preclinical development by GlyProVac. It is designed to target the YghJ antigen, a highly conserved protein found across various Escherichia coli strains, including enterotoxigenic E. coli (ETEC). The vaccine utilizes GlyProVac's proprietary BEMAP (Bacterial Expression of Mammalian Proteins) technology platform, which employs mass spectrometry to identify and replicate O-linked protein glycosylation patterns. By using hyperglycosylated YghJ polypeptides, GPV02 mimics the natural decoration of bacterial proteins to trigger a robust and specific immune response. The candidate is being developed as a multi-indication vaccine for enterotoxigenic E. coli infections, diarrhea, urinary tract infections (UTIs), healthcare-associated UTIs, and neonatal sepsis. In 2024, it received funding from CARB-X to support its development as a maternal vaccine aimed at protecting newborns from neonatal sepsis caused by E. coli.